Science v1 – Chimeric Therapeutics

Chimeric is committed to bringing the promise of cell therapy to life for more patients.

To fulfill our mission, we are focused on discovering, developing and commercializing the most promising and innovative cell therapies.

CHM 1101 (CLTX CAR T)

CHM 1101 (CLTX CAR T) is an optimized first-in-class CAR T cell therapy that uniquely utilizes Chlorotoxin (CLTX), a 36-amino acid peptide derived from deathstalker scorpion venom as its tumour targeting domain.

CHM 1101 has been shown to more specifically and broadly target GBM cells than other immunotherapy targets like HER2, EGFR and IL13, through recognition of a receptor complex composed of membrane-bound matrix metalloprotease 2 (MMP2)
CCHM 1101 demonstrated excellent preclinical safety with no off tumour recognition of normal human or murine cells or tissues in preclinical models, consistent with the documented safety of administering CLTX containing agents in humans
CCHM 1101 demonstrated potent anti-tumour activity in vivo with significantly improved survival in mice

CHM 1101 is currently in clinical trials in patients with recurrent or progressive glioblastoma.

Based upon evidence of CLTX binding in other solid tumours, preclinical studies are currently ongoing to determine the potential of CHM 1101 in solid tumours such as melanoma, colorectal cancer and prostate cancer.

CHM 2101 (CDH17 CAR T)

CHM 2101 (CDH17 CAR T) is an optimized 3rd generation CAR T cell therapy that is the first to target CDH17.

CHM 2101 was optimized over a decade of development to address the high unmet medical needs of patients with neuroendocrine tumours
A potent anti cancer antibody that optimally and specifically bound to neuroendocrine tumor cells was developed and through robust target validation, CDH17 was identified as the antigen target
The CDH17 CAR T was optimized as a 3rd generation construct with both CD28 and 41BB costimulatory domains
CHM 2101 preclinical evidence have demonstrated a unique potency for solid tumours with complete eradication of tumour cells with no relapse

Preclinical studies also demonstrated no toxicity to normal tissues.

Although CDH17 is known to be expressed on normal epithelial cells, the CDH17 CAR T cells only infiltrated the tumour cells, sparing the normal cells, even when they expressed CDH17.

In normal cells, CDH17 is inaccessible as it is hidden beneath tight junctions that reinforce the barriers of normal cells while in cancer, CDH17 upregulation results in exposure of the CDH17 on the cancer cells allowing the CAR T to detect and bind to it.

With the evidence of high CDH 17 expression in solid tumours, CHM 2101 is being studied in neuroendocrine tumours as well as in gastrointestinal (GI) cancers such as colorectal, pancreatic and gastric cancer.

Collaborations

Ongoing research collaboration with Dr Christine Brown and the Christine Brown Laboratory at the City of Hope Cancer Center.

Ongoing research collaboration with Dr Xianxin Hua and the Hua Laboratory at the University of Pennsylvania.

Ongoing research collaboration with Dr Christine Brown and the Christine Brown Laboratory at the City of Hope Cancer Center.

Ongoing research collaboration with Dr Xianxin Hua and the Hua Laboratory at the University of Pennsylvania.

Chimeric is actively engaged in a strategic business development to further our mission to bring the promise of cell therapy to more patients with cancer.
We welcome inquiries on collaborating with us.

About cell therapy

What is cell therapy?

Cell therapy is the transfer of intact, live cells into a patient to help lessen or cure a disease.
The most common and simple type of cell therapy is a blood transfusion.
Other commonly known cell therapies include red and white blood cell transfusions and bone marrow transplants.

Autologous vs. Allogeneic Cell Therapies

When the cells that are used for the therapy originate from the patient it is referred to as an autologous cell therapy.
When the cells that are used for the therapy originate from a donor it is referred to as an allogeneic cell therapy

What is Autologous CAR T Cell Therapy?

Autologous Chimeric Antigen Receptor (CAR) T cell therapy is a type of cell therapy in which a patient’s own T cells are reprogrammed in a laboratory to attack specific cancer cells.

CAR T cell therapies have shown transformative benefit in patients with blood cancers that have not responded or stopped responding to other therapies resulting in global approvals for CAR T cell therapies for certain types of Lymphoma, Leukemia and Multiple Myeloma.

How does Autologous CAR T cell therapy work?

Click icon to download
Poster PDF (1 MB)
or
Click on the image to see in Full screen